Skip to content
Search

Latest Stories

US health regulator approves Cipla’s inhalation solution

PHARMACEUTICAL major Cipla received final consent from the US health regulator for Arformoterol Tartrate inhalation solution.

The approved product is used to treat conditions like chronic bronchitis and emphysema in the US market.


The company has received final approval for its abbreviated new drug application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL from the United States Food and Drug Administration (US FDA), Cipla said in a regulatory filing on Wednesday (23).

It is a generic version of Sunovion Pharmaceuticals Inc's Brovana.

Brovana is used in maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Brovana had sales of around $438 million (£314m) in the US for the 12-month period ending April 2021.

The new product is available for shipping immediately, Cipla said.

More For You

Jaguar Land Rover

Vehicle production came to a complete halt on September (1) with JLR unable to resume global operations until five weeks later

Getty Images

Jaguar Land Rover production plunges 43 per cent following devastating cyber attack

Highlights

  • JLR produced only 59,200 cars in final quarter of 2025 compared to 104,400 previous year, down 43 per cent due to cyber attack fallout.
  • Operations halted globally for five weeks from September after August breach described as Britain's most expensive cyber attack.
  • Retail sales plummeted 25 per cent to 79,600 vehicles; company preparing to launch £100,000+ electric Jaguar saloon later this year.

Car production at Jaguar Land Rover plummeted by 45,000 vehicles in the final quarter of 2025 as the British automotive giant struggled with the aftermath of what experts have described as the most expensive cyber attack in British history.

The company revealed total output in the three months to December was down 43 per cent compared to last year, despite restarting factory lines in the second week of October. JLR produced just 59,200 cars in the final quarter of 2025, compared to 104,400 the previous year.

Keep ReadingShow less